Dr. Jeffrey Jones on Efficacy of Idelalisib/Ofatumumab Combination in CLL

Jeffrey Jones, MD
Published: Sunday, May 31, 2015



Jeffrey Jones, MD, MPH, Assistant Professor of Internal Medicine and section head of the Chronic Lymphocytic Leukemia (CLL) research program at Ohio State University, discusses the results of a phase III randomized, controlled study evaluating idelalisib (Zydelig) in combination with ofatumumab (Arzerra) compared to ofatumumab alone for previously treated CLL.

The number of agents that have traditionally been available for patients with relapsed or refractory CLL has been limited, says Jones. Patients in this study received 6 months of ofatumumab in both arms, and patients in the combination arm received twice-daily idelalisib to be continued until disease progression or intolerable side effects.

Progression-free survival was significantly improved in the combination arm, with a median progression-free survival of just over 16 months, compared to 8 months in the ofatumumab-only arm, says Jones. The overall response rate was 75% in the combination arm versus 18% in the single agent arm.

<<< View more from the 2015 ASCO Annual Meeting



Jeffrey Jones, MD, MPH, Assistant Professor of Internal Medicine and section head of the Chronic Lymphocytic Leukemia (CLL) research program at Ohio State University, discusses the results of a phase III randomized, controlled study evaluating idelalisib (Zydelig) in combination with ofatumumab (Arzerra) compared to ofatumumab alone for previously treated CLL.

The number of agents that have traditionally been available for patients with relapsed or refractory CLL has been limited, says Jones. Patients in this study received 6 months of ofatumumab in both arms, and patients in the combination arm received twice-daily idelalisib to be continued until disease progression or intolerable side effects.

Progression-free survival was significantly improved in the combination arm, with a median progression-free survival of just over 16 months, compared to 8 months in the ofatumumab-only arm, says Jones. The overall response rate was 75% in the combination arm versus 18% in the single agent arm.

<<< View more from the 2015 ASCO Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x